Structure Therapeutics Inc (GPCR)

$44.51 -0.49 (-1.09%)
Market Cap 3.16B
Revenue (ttm) 0.00
Net Income (ttm) -141.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,152,000
Avg Vol 814,934
Day's Range N/A - N/A
Shares Out 71.08M
Stochastic %K 75%
Beta -1.35
Analysts Strong Sell
Price Target $106.44

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
SuperGreenToday
SuperGreenToday Jun. 18 at 4:25 PM
$GPCR Share Price: $45.60 Contract Selected: Dec 18, 2026 $45 Calls Buy Zone: $9.35 – $11.55 Target Zone: $17.36 – $21.21 Potential Upside: 75% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Doozio
Doozio Jun. 18 at 12:04 AM
$GPCR chop chop huckleberries ONTA 🐒🍌🧠⏰♾️
0 · Reply
Theflash88
Theflash88 Jun. 17 at 9:51 PM
$GPCR Somethings cooking…
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jun. 17 at 9:50 PM
$GPCR confirmation today. Steady climbing from here i think.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jun. 17 at 9:48 PM
$GPCR risky in my opinion unless you are selling way out of the money calls. Gla. NfA
0 · Reply
IM11
IM11 Jun. 17 at 9:07 PM
$GPCR Seems to me that there is a buyout / partnership announcement window between now and July 1st prior to the end of Q2. Once we pass July 1st, we get into quiet windows for Q2 results & start to get too late to be well ahead of GPCR's Phase 3 kick-off which likely has the first patient dosing in August. Monday June 22nd and June 29th look like good announcement days to me ;) Abbvie, Sanofi, & Roche should all want/need GPCR pretty badly to play in the Obesity market. The long weekend for the stock market due to Juneteenth seems like an ideal window to sign some papers..... we can dream!
0 · Reply
FREEAMERICA
FREEAMERICA Jun. 17 at 8:59 PM
$GPCR trading like a buyouts coming
0 · Reply
AR15lph
AR15lph Jun. 17 at 8:33 PM
$GPCR Done selling covered calls , waiting for good news!
0 · Reply
Kylenorth
Kylenorth Jun. 17 at 8:00 PM
$GPCR strong finish on volume!!! something cooking
0 · Reply
Kylenorth
Kylenorth Jun. 17 at 7:02 PM
$GPCR this is going to the moon!!! BO for 120
0 · Reply
Latest News on GPCR
Structure Therapeutics Transcript: AGM 2026

Jun 17, 2026, 12:00 PM EDT - 2 days ago

Structure Therapeutics Transcript: AGM 2026

The Next Phase Of The Obesity Drug Race

Jun 13, 2026, 2:00 PM EDT - 6 days ago

The Next Phase Of The Obesity Drug Race

LLY NVO

Structure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright

2026-06-11T10:06:10.000Z - 8 days ago

Structure Therapeutics price target lowered to $70 from $100 at H.C. Wainwright

Structure Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 10 days ago

Structure Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Structure's experimental obesity pill shows no signs of liver injury

Jun 5, 2026, 5:16 PM EDT - 14 days ago

Structure's experimental obesity pill shows no signs of liver injury

Structure Therapeutics announces ACCESS trial data published in Nature Medicine

2026-06-05T20:10:53.000Z - 14 days ago

Structure Therapeutics announces ACCESS trial data published in Nature Medicine

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Jun 5, 2026, 4:05 PM EDT - 14 days ago

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Structure Therapeutics Slides: Corporate presentation

Jun 5, 2026, 7:00 AM EDT - 14 days ago

Structure Therapeutics Slides: Corporate presentation

Structure Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 16 days ago

Structure Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

May 26, 2026, 4:05 PM EDT - 24 days ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

May 7, 2026, 4:05 PM EDT - 6 weeks ago

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 6 weeks ago

Structure Therapeutics Earnings release: Q1 2026

Structure Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 6 weeks ago

Structure Therapeutics Quarterly report: Q1 2026

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Apr 27, 2026, 4:05 PM EDT - 7 weeks ago

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Canaccord starts Structure Therapeutics on oral weight loss pipeline

2026-04-27T12:58:41.000Z - 7 weeks ago

Canaccord starts Structure Therapeutics on oral weight loss pipeline

Structure Therapeutics initiated with a Buy at Canaccord

2026-04-27T10:00:27.000Z - 7 weeks ago

Structure Therapeutics initiated with a Buy at Canaccord

Structure Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Structure Therapeutics Proxy statement: Proxy filing

Structure Therapeutics appoints Matthew Lang as COO

2026-04-14T20:17:51.000Z - 2 months ago

Structure Therapeutics appoints Matthew Lang as COO

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Apr 14, 2026, 4:05 PM EDT - 2 months ago

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright

2026-03-16T15:55:34.000Z - 3 months ago

Structure Therapeutics price target lowered to $100 from $114 at H.C. Wainwright

Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

2026-03-16T15:10:26.000Z - 3 months ago

Structure’s GLP-1 pill could put company on M&A radar, Barron’s says

LLY NVO

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Mar 16, 2026, 10:46 AM EDT - 3 months ago

Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?

Structure Therapeutics Transcript: Study result

Mar 16, 2026, 8:30 AM EDT - 3 months ago

Structure Therapeutics Transcript: Study result

Structure Therapeutics Press release: Study result

Mar 16, 2026, 8:30 AM EDT - 3 months ago

Structure Therapeutics Press release: Study result

Structure Therapeutics Slides: Study result

Mar 16, 2026, 8:30 AM EDT - 3 months ago

Structure Therapeutics Slides: Study result

Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study

2026-03-16T11:22:17.000Z - 3 months ago

Structure Therapeutics: Aleniglipron achieved meaningful weight loss in study

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright

2026-03-02T11:26:56.000Z - 3 months ago

Structure Therapeutics price target raised to $114 from $90 at H.C. Wainwright

Structure Therapeutics price target lowered to $113 from $120 at Citizens

2026-02-27T10:55:51.000Z - 4 months ago

Structure Therapeutics price target lowered to $113 from $120 at Citizens

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Feb 26, 2026, 4:02 PM EST - 4 months ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Structure Therapeutics Annual report: Q4 2025

Feb 26, 2026, 4:00 PM EST - 4 months ago

Structure Therapeutics Annual report: Q4 2025

Structure Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 4:00 PM EST - 4 months ago

Structure Therapeutics Earnings release: Q4 2025

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 4 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN LLY NVO PFE VKTX

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

2026-01-30T15:51:54.000Z - 5 months ago

Structure Therapeutics emerges as top M&A target for big pharma, Axios says

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

2026-01-22T11:51:35.000Z - 5 months ago

Structure Therapeutics price target raised to $105 from $65 at JPMorgan

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Jan 21, 2026, 10:05 AM EST - 5 months ago

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Structure Therapeutics price target raised to $140 from $90 at Guggenheim

2026-01-20T12:26:42.000Z - 5 months ago

Structure Therapeutics price target raised to $140 from $90 at Guggenheim

Structure Therapeutics moved to Buy rating at Goldman Sachs

2026-01-19T22:30:27.000Z - 5 months ago

Structure Therapeutics moved to Buy rating at Goldman Sachs

LLY

Structure CEO Ray Stevens talks its obesity drug portfolio

Jan 15, 2026, 6:21 PM EST - 5 months ago

Structure CEO Ray Stevens talks its obesity drug portfolio

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

2026-01-14T18:05:20.000Z - 5 months ago

Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher

LLY NVO PFE TERN VKTX

Structure Therapeutics rises 14.1%

2026-01-13T17:05:46.000Z - 5 months ago

Structure Therapeutics rises 14.1%

Structure Therapeutics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 5 months ago

Structure Therapeutics Slides: Corporate presentation

Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

2025-12-19T13:45:27.000Z - 6 months ago

Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 11, 2025, 4:01 PM EST - 6 months ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 11:15 PM EST - 6 months ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 6 months ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 11:20 AM EST - 6 months ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure Therapeutics Transcript: Study Update

Dec 8, 2025, 8:30 AM EST - 6 months ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Dec 8, 2025, 8:30 AM EST - 6 months ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Dec 8, 2025, 8:30 AM EST - 6 months ago

Structure Therapeutics Slides: Study Update

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:14 AM EST - 6 months ago

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 8, 2025, 8:00 AM EST - 6 months ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Dec 7, 2025, 6:20 PM EST - 6 months ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Final Trade: UBER, CRWV, GPCR, DIS

Nov 10, 2025, 6:21 PM EST - 7 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:01 PM EST - 8 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Structure Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 8 months ago

Structure Therapeutics Quarterly report: Q3 2025

Structure Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 8 months ago

Structure Therapeutics Earnings release: Q3 2025

Fast Money: DAL, ROKU, AAPL, GPCR

Nov 5, 2025, 6:21 PM EST - 8 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Structure Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 10:45 AM EDT - 10 months ago

Structure Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Structure Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 10 months ago

Structure Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 11 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Structure Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

Structure Therapeutics Quarterly report: Q2 2025

Structure Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

Structure Therapeutics Earnings release: Q2 2025

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 1 year ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 1 year ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Structure Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Structure Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Structure Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Earnings release: Q1 2025

Structure Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Quarterly report: Q1 2025

Structure Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Structure Therapeutics Proxy statement: Proxy Filing

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 1 year ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 1 year ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 1 year ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 1:00 PM EDT - 1 year ago

Structure Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Structure Therapeutics Annual report: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Structure Therapeutics Annual report: Q4 2024

Structure Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Structure Therapeutics Earnings release: Q4 2024

Structure Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 10:30 AM EST - 1 year ago

Structure Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Structure Therapeutics Transcript: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Slides: Study Update

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 3:00 AM EST - 1 year ago

Structure Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Transcript: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Slides: Study Update

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Structure Therapeutics Quarterly report: Q3 2024

Structure Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Structure Therapeutics Earnings release: Q3 2024

Structure Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 9:10 AM EDT - 1 year ago

Structure Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 10:00 AM EDT - 1 year ago

Structure Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Quarterly report: Q2 2024

Structure Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Earnings release: Q2 2024

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 2 years ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 2 years ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 2 years ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 2 years ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 2 years ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 2 years ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 2 years ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Transcript: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Transcript: Study Update

Structure Therapeutics Press release: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Press release: Study Update

Structure Therapeutics Slides: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Slides: Study Update

Structure Therapeutics Registration statement: Registration Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Registration statement: Registration Filing

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 2 years ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Structure Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Quarterly report: Q1 2024

Structure Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Earnings release: Q1 2024

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

May 7, 2024, 11:33 AM EDT - 2 years ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Structure Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Proxy statement: Proxy Filing

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Apr 16, 2024, 7:09 PM EDT - 2 years ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Structure Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Mar 9, 2024, 2:30 AM EST - 2 years ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 4:05 PM EST - 2 years ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Mar 8, 2024, 8:30 AM EST - 2 years ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

SuperGreenToday
SuperGreenToday Jun. 18 at 4:25 PM
$GPCR Share Price: $45.60 Contract Selected: Dec 18, 2026 $45 Calls Buy Zone: $9.35 – $11.55 Target Zone: $17.36 – $21.21 Potential Upside: 75% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Doozio
Doozio Jun. 18 at 12:04 AM
$GPCR chop chop huckleberries ONTA 🐒🍌🧠⏰♾️
0 · Reply
Theflash88
Theflash88 Jun. 17 at 9:51 PM
$GPCR Somethings cooking…
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jun. 17 at 9:50 PM
$GPCR confirmation today. Steady climbing from here i think.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jun. 17 at 9:48 PM
$GPCR risky in my opinion unless you are selling way out of the money calls. Gla. NfA
0 · Reply
IM11
IM11 Jun. 17 at 9:07 PM
$GPCR Seems to me that there is a buyout / partnership announcement window between now and July 1st prior to the end of Q2. Once we pass July 1st, we get into quiet windows for Q2 results & start to get too late to be well ahead of GPCR's Phase 3 kick-off which likely has the first patient dosing in August. Monday June 22nd and June 29th look like good announcement days to me ;) Abbvie, Sanofi, & Roche should all want/need GPCR pretty badly to play in the Obesity market. The long weekend for the stock market due to Juneteenth seems like an ideal window to sign some papers..... we can dream!
0 · Reply
FREEAMERICA
FREEAMERICA Jun. 17 at 8:59 PM
$GPCR trading like a buyouts coming
0 · Reply
AR15lph
AR15lph Jun. 17 at 8:33 PM
$GPCR Done selling covered calls , waiting for good news!
0 · Reply
Kylenorth
Kylenorth Jun. 17 at 8:00 PM
$GPCR strong finish on volume!!! something cooking
0 · Reply
Kylenorth
Kylenorth Jun. 17 at 7:02 PM
$GPCR this is going to the moon!!! BO for 120
0 · Reply
Wallst45
Wallst45 Jun. 17 at 4:07 PM
$GPCR nice move up yay
0 · Reply
Kylenorth
Kylenorth Jun. 17 at 3:48 PM
$GPCR this thing is going to explode!!! BO coming this year
0 · Reply
biolover
biolover Jun. 17 at 3:40 PM
$ALT $GPCR $VKTX Please don’t add Viking to this ahitrg list.
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 17 at 2:05 PM
$VKTX has been around for years and not been bought; why is that? Long $ALT ; loved $GPCR before it blew up. Why Viking now?
1 · Reply
chartistmind
chartistmind Jun. 17 at 1:46 PM
$GPCR just amazing. Another 20%+ 🚀 ripper within just days memorialized into the stocktits records.
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 17 at 12:37 PM
$GALT is still on my radar… i like $ALT and $GPCR and $VKTX much more, but Gallectin is a survivor 🤔
0 · Reply
PlutoAnalyses
PlutoAnalyses Jun. 16 at 6:42 AM
$GPCR, my analysis of the company describes how the future of GLP-1’s could shift from an efficacy discussion to a safety discussion. There are strong pure-play GLP-1 drugs like $VKTX, but if adjusted for safety, the oral drugs' utility might be different. (VKTX’s strength lies in the maintenance study, and maybe they can improve the titration; I am just trying to elaborate on a point.) (I don’t want to say one is better than the other here) Here is the link for those of you who want to deep dive: https://open.substack.com/pub/plutoanalyses/p/structure-therapeutics-analysis-whats?r=5e6tza&utm_medium=ios
0 · Reply
AR15lph
AR15lph Jun. 15 at 4:39 PM
$GPCR rolled down 30 of the 6/18 $55 covered cals to the $50 strike price collecting $.52.
0 · Reply
NYG4ever
NYG4ever Jun. 15 at 4:24 PM
$GPCR
0 · Reply
Zorrodoc
Zorrodoc Jun. 15 at 3:10 PM
$GPCR everything skyrocketing but GPCR. Why? Lol
0 · Reply
TrustButVerifi
TrustButVerifi Jun. 13 at 4:01 PM
$GPCR $VKTX piss on all of that other than Lilly TZP if you get the math. That is the king til it gets dethroned by VK2735 Viking will get 1/2 of TAM in time. Look up Lipitor history and u might might get it.
1 · Reply
Wallst45
Wallst45 Jun. 13 at 3:59 PM
$GPCR this will get bought out
0 · Reply